Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Benzinga · 3d ago
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.